Apyx Medical Corp (APYX) shareholders
APYXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/3035% above fair value
$2.89−0.11 (-3.67%)
Close on Nov 12, 2026Market cap $121.74MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
58.5%
25M of 42M shares
Institutional holders
68
11 new, 10 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) | 4,112,705 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Royce & Associates LP | 3,274,064 | 7.81% | 13G (passive) amendment | Jun 30, 2026 |
| Constantinos Christofilis Joint filing with Archon Capital Management LLC (8.99%), Strategos Fund, L.P. (5.18%) | 3,115,281 | 8.99% | 13G (passive) | Oct 31, 2024 |
| Kanen Wealth Management LLC Joint filing with Kanen David (5.40%) | 2,280,518 | 5.40% | 13G (passive) | Oct 21, 2026 |
| Stavros G. Vizirgianakis | 1,746,191 | 5.04% | 13D (active) amendment | May 7, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of APYX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6,540,496 | 15.53% | $29.37M | +3,100,192 | 0.49% |
| Royce & Associates LP | 3,274,064 | 7.77% | $14.70M | +662,840 | 0.12% |
| Archon Capital Management LLC | 2,644,717 | 6.28% | $11.87M | −146,206 | 4.82% |
| Vanguard Capital Management LLC | 1,534,847 | 3.64% | $6.89M | −20,425 | 0.00% |
| Essex Investment Management Co LLC | 1,136,630 | 2.70% | $5.10M | +235,232 | 0.67% |
| AIGH Capital Management LLC | 1,128,343 | 2.68% | $5.07M | +23,373 | 0.32% |
| Silverberg Bernstein Capital Management LLC | 1,039,641 | 2.47% | $4.67M | −1,429 | 1.79% |
| Commonwealth Equity Services, LLC | 649,061 | 1.54% | $2.91M | – | 0.00% |
| Horizon Kinetics Asset Management LLC | 585,000 | 1.39% | $2.63M | −30,000 | 0.03% |
| BlackRock, Inc. | 560,986 | 1.33% | $2.52M | +33,238 | 0.00% |
| Renaissance Technologies LLC | 554,278 | 1.32% | $2.49M | +251,883 | 0.00% |
| Taylor Frigon Capital Management LLC | 413,602 | 0.98% | $1.86M | −957 | 0.87% |
| Geode Capital Management, LLC | 400,600 | 0.95% | $1.80M | +9,244 | 0.00% |
| Legato Capital Management LLC | 382,762 | 0.91% | $1.72M | +101,873 | 0.14% |
| Sei Investments Co | 281,029 | 0.67% | $1.26M | −317,226 | 0.00% |
| Huntleigh Advisors, Inc. | 263,231 | 0.62% | $1.18M | +17,311 | 0.17% |
| Millennium Management LLC | 242,663 | 0.58% | $1.09M | −19,395 | 0.00% |
| Marshall Wace, Llp | 236,466 | 0.56% | $1.06M | +174,630 | 0.00% |
| Vanguard Fiduciary Trust Co | 224,021 | 0.53% | $1.01M | +21,340 | 0.00% |
| Susquehanna International Group, Llp | 216,263 | 0.51% | $971.02K | −51,298 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 68 | 25M | 58.5% | 11 / 24 | 22 / 10 | 5M | 1M |
| Q1 2026 | 67 | 21M | 49.4% | 16 / 23 | 16 / 7 | 5M | 1M |
| Q4 2025 | 59 | 19M | 45.4% | 21 / 14 | 10 / 9 | 4M | 0M |
| Q3 2025 | 47 | 16M | 37.4% | 11 / 9 | 10 / 3 | 0M | 1M |
| Q2 2025 | 39 | 16M | 37.5% | 4 / 10 | 14 / 7 | 1M | 0M |
| Q1 2025 | 43 | 16M | 37.5% | 3 / 8 | 18 / 5 | 0M | 1M |
| Q4 2024 | 45 | 16M | 37.8% | 5 / 12 | 16 / 3 | 4M | 0M |
| Q3 2024 | 45 | 13M | 30.4% | 4 / 7 | 15 / 7 | 1M | 1M |
| Q2 2024 | 49 | 13M | 31.1% | 5 / 13 | 19 / 7 | 1M | 1M |
| Q1 2024 | 51 | 13M | 31.8% | 3 / 10 | 21 / 14 | 1M | 5M |
| Q4 2023 | 62 | 18M | 42.2% | 12 / 22 | 14 / 12 | 2M | 3M |
| Q3 2023 | 62 | 18M | 43.5% | 18 / 18 | 10 / 11 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
20 funds held APYX in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of APYX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,095,524 | 2.60% | $4.92M | 0.00% | Jun 30, 2026 |
| Royce Small-Cap Opportunity Fund | 698,945 | 1.66% | $3.14M | 0.22% | Jun 30, 2026 |
| Royce Micro-Cap Fund | 586,780 | 1.39% | $2.63M | 0.62% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 399,651 | 0.95% | $1.79M | 0.00% | Jun 30, 2026 |
| 1290 Essex Small Cap Growth Fund | 276,178 | 0.66% | $1.13M | 0.97% | Jul 31, 2026 |
| Royce Capital Fund - Micro-Cap Portfolio | 215,125 | 0.51% | $965.91K | 0.69% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 179,731 | 0.43% | $718.03K | 0.00% | May 31, 2026 |
| Taylor Frigon Core Growth Fund | 128,436 | 0.30% | $513.10K | 1.42% | May 31, 2026 |
| iShares Micro-Cap ETF | 122,285 | 0.29% | $549.06K | 0.04% | Jun 30, 2026 |
| Siit Small Cap Ii Fund | 87,900 | 0.21% | $351.16K | 0.14% | May 31, 2026 |
| Fidelity Total Market Index Fund | 56,118 | 0.13% | $224.19K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 55,300 | 0.13% | $248.30K | 0.17% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 52,645 | 0.12% | $210.32K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 23,327 | 0.06% | $93.19K | 0.00% | May 31, 2026 |
| Venerable US Small Cap Fund | 22,033 | 0.05% | $98.93K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Charles D. Goodwin II | Chief Executive Officer, Director | 90,000 | 0.21% | Jun 15, 2026 |
| Shawn David Roman | Chief Operating Officer | 15,000 | 0.04% | Jun 17, 2026 |
| Moshe Citronowicz | Sr. V.P. of Operations | 493,504 | 1.17% | Jun 15, 2026 |
| Matthew C. Hill | Chief Financial Officer | 8,500 | 0.02% | Jun 15, 2026 |
| Lawrence Waldman | Director | 49,877 | 0.12% | Jul 2, 2026 |
| Minnie Baylor-Henry | Director | – | – | Jun 15, 2026 |
| Stavros G. Vizirgianakis | Director | 2,196,191 | 5.21% | Jun 15, 2026 |
| Wendy Lauren Levine | Director | – | – | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lawrence Waldman Director | Jun 30, 2026 | Tax withholding | −5,024 | $4.49 | $22.56K | 12,314 |
| Lawrence Waldman Director | Jun 30, 2026 | Option exercise | +12,000 | $1.88 | $22.56K | 17,338 |
| Shawn David Roman Chief Operating Officer | Jun 15, 2026 | Option exercise | +15,000 | $3.23 | $48.45K | 15,000 |
| Shawn David Roman Chief Operating Officer | Jun 15, 2026 | Tax withholding | −10,533 | $4.60 | $48.45K | 16,467 |
| Stavros G. Vizirgianakis Director | Jun 11, 2026 | Award | +450,000 | – | – | 2,196,191 |
| Moshe Citronowicz Senior Vice President | Mar 15, 2026 | Option exercise | +37,000 | $1.80 | $66.60K | 493,504 |
| Shawn David Roman Chief Operating Officer | Jan 27, 2026 | Option exercise | +12,000 | $1.80 | $21.60K | 12,000 |
| Matthew C. Hill Chief Financial Officer | Aug 13, 2024 | Buy | +6,000 | $1.13 | $6.78K | 8,500 |
| Matthew C. Hill Chief Financial Officer | Aug 13, 2024 | Buy | +5,336 | $1.13 | $6.03K | 7,836 |
| Matthew C. Hill Chief Financial Officer | Dec 12, 2023 | Buy | +2,500 | $2.19 | $5.48K | 2,500 |
| Charles D. Goodwin II Chief Executive Officer, Director | Nov 14, 2023 | Buy | +50,000 | $1.57 | $78.50K | 90,000 |
| Lawrence Waldman Director | Jul 12, 2023 | Option exercise | +5,338 | $2.97 | $15.85K | 5,338 |
| Todd Hornsby Executive Vice President | Jun 26, 2023 | Option exercise | +15,000 | $1.77 | $26.55K | 15,000 |
| Todd Hornsby Executive Vice President | Jun 26, 2023 | Sale(10b5-1 plan) | −15,000 | $7.56 | $113.40K | 0 |
| Todd Hornsby Executive Vice President | Jun 26, 2023 | Sale(10b5-1 plan) | −15,000 | $7.56 | $113.40K | 40 |
| Todd Hornsby Executive Vice President | Jun 26, 2023 | Option exercise | +15,000 | $1.77 | $26.55K | 15,000 |
| Michael Geraghty Director | Jun 6, 2023 | Option exercise | +10,000 | $2.79 | $27.90K | 27,500 |
| Charles D. Goodwin II Chief Executive Officer, Director | Aug 29, 2022 | Buy | +2,000 | $5.93 | $11.86K | 30,250 |
| Charles D. Goodwin II Chief Executive Officer, Director | Aug 29, 2022 | Buy | +9,750 | $5.97 | $58.21K | 40,000 |
| Moshe Citronowicz Sr. V.P. of Operations | Jul 11, 2022 | Option exercise | +30,000 | $2.54 | $76.20K | 456,504 |
| Lawrence Waldman Director | Jul 11, 2022 | Option exercise | +24,000 | $2.54 | $60.96K | 37,563 |
| Michael Geraghty Director | Jul 6, 2022 | Option exercise | +4,000 | $2.54 | $10.16K | 17,500 |
| Andrew Makrides Director | Jul 5, 2022 | Tax withholding | −13,583 | $6.14 | $83.40K | 624,389 |
| Andrew Makrides Director | Jul 5, 2022 | Option exercise | +30,000 | $2.54 | $76.20K | 637,972 |
| Lawrence Waldman Director | May 19, 2022 | Option exercise | +8,000 | $2.79 | $22.32K | 13,563 |
| Michael Geraghty Director | May 11, 2022 | Option exercise | +6,000 | $2.79 | $16.74K | 13,500 |
| Craig A. Swandal Director | Mar 21, 2022 | Option exercise | +17,000 | $4.98 | $84.66K | 17,000 |
| Craig A. Swandal Director | Jan 7, 2022 | Option exercise | +7,173 | $9.42 | $67.57K | 60,173 |
| Lawrence Waldman Director | Mar 8, 2021 | Option exercise | +5,563 | $2.81 | $15.63K | 5,563 |
| Michael Geraghty Director | Mar 5, 2021 | Option exercise | +7,500 | $2.81 | $21.08K | 7,500 |
| Craig A. Swandal Director | Oct 7, 2020 | Option exercise | +7,084 | $7.28 | $51.57K | 17,000 |
| Charles D. Goodwin II Chief Executive Officer, Director | May 13, 2020 | Buy | +28,250 | $3.30 | $93.23K | 28,250 |
| Craig A. Swandal Director | Mar 4, 2020 | Option exercise | +9,916 | $7.28 | $72.19K | 17,000 |
| Craig A. Swandal Director | Oct 1, 2019 | Option exercise | +10,000 | $5.30 | $53.00K | 36,000 |
| Craig A. Swandal Director | Apr 4, 2019 | Exercise | +6,000 | $5.30 | $31.80K | 26,000 |
| Craig A. Swandal Director | Apr 4, 2019 | Option exercise | +2,000 | $2.37 | $4.74K | 20,000 |
| Craig A. Swandal Director | Jan 10, 2019 | Option exercise | +10,000 | $2.37 | $23.70K | 10,000 |
| Craig A. Swandal Director | Jan 10, 2019 | Option exercise | +8,000 | $5.30 | $42.40K | 18,000 |
| Andrew Makrides Director | Nov 8, 2018 | Gift | −2,000 | $6.84 | $13.68K | 605,972 |
| Andrew Makrides Director | Nov 8, 2018 | Gift | −2,000 | $6.84 | $13.68K | 607,972 |
| Andrew Makrides Director | Nov 8, 2018 | Gift | −2,000 | $6.84 | $13.68K | 609,972 |
| John J. McCarthy III Chief CommercializationOfficer | Aug 17, 2016 | Buy | +90,750 | $3.30 | $299.48K | 115,750 |
| John J. McCarthy III Chief Commercialization Office | Dec 22, 2015 | Buy | +25,000 | $1.98 | $49.50K | 25,000 |
| Moshe Citronowicz Sr. V.P. of Operations | Dec 21, 2015 | Buy | +20,000 | $1.84 | $36.80K | 426,504 |
| Robert Gershon Chief Executive Officer, Director | Dec 21, 2015 | Buy | +10,000 | $1.82 | $18.20K | 30,000 |
| Robert Gershon Chief Executive Officer, Director | Aug 14, 2015 | Buy | +20,000 | $2.39 | $47.80K | 20,000 |
| Point Partners Llc Great – | Mar 17, 2015 | Award | +480,000 | $2.50 | $1.20M | 480,000 |
| Andrew Makrides Director | Sep 19, 2014 | Option exercise | +25,000 | $2.13 | $53.25K | 624,213 |
| Andrew Makrides Director | Sep 19, 2014 | Tax withholding | −12,241 | $4.35 | $53.25K | 611,972 |
| J. Robert Saron President, Director | Sep 19, 2014 | Option exercise | +12,500 | $2.13 | $26.63K | 399,819 |
| J. Robert Saron President, Director | Sep 19, 2014 | Tax withholding | +6,121 | $4.35 | $26.63K | 393,698 |
| George W. Kromer Director | Oct 1, 2013 | Gift | −4,000 | $2.91 | $11.64K | 247,508 |
| George W. Kromer Director | Dec 5, 2012 | Gift | −5,000 | $2.65 | $13.25K | 251,508 |
| George W. Kromer Director | Sep 6, 2012 | Gift | −5,000 | $2.66 | $13.30K | 256,508 |
| Gregory Alan Konesky Director | Dec 23, 2011 | Sale | −750 | $2.40 | $1.80K | 1,750 |
| Universal Growth Investment Trust RENN Director | Aug 25, 2011 | Buy | +7,100 | $2.70 | $19.17K | 1,247,800 |
| Universal Growth Investment Trust RENN Director | Aug 24, 2011 | Buy | +14,100 | $2.66 | $37.51K | 1,240,770 |
| Universal Growth Investment Trust RENN Director | Aug 23, 2011 | Buy | +11,600 | $2.55 | $29.58K | 1,226,600 |
| Universal Growth Investment Trust RENN 10% owner | Aug 9, 2011 | Buy | +100,000 | $2.45 | $245.00K | 1,215,000 |
| Universal Growth Investment Trust RENN 10% owner | Aug 9, 2011 | Buy | +15,000 | $2.09 | $31.35K | 1,115,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.62%
0M shares short
Days to cover
2.1
At 0M shares a day
Change since last report
+14.8%
From 0M shares
Short volume, 20 days
29.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Apyx Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,189 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Todd Hornsby Officer | Jun 21, 2023 | 15,000 | $105.30K | Jun 21, 2023 | Stock Option Exercise |
See a number that looks wrong?